Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP2478] to PDGFR alpha (phospho Y720)
- Suitable for: WB, Flow Cyt
- Reacts with: Mouse, Rat, Human
Product nameAnti-PDGFR alpha (phospho Y720) antibody [EP2478]
See all PDGFR alpha primary antibodies
DescriptionRabbit monoclonal [EP2478] to PDGFR alpha (phospho Y720)
ab134068 only detects PDGFR alpha phosphorylated at Tyrosine 720.
Tested applicationsSuitable for: WB, Flow Cytmore details
Unsuitable for: ICC,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
corresponding to Human PDGFR alpha.
- NIH 3T3 cell lysates, treated with Pervanadate.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab134068 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 190 kDa (predicted molecular weight: 122 kDa).|
|Flow Cyt||1/200 - 1/1000.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
FunctionReceptor that binds both PDGFA and PDGFB and has a tyrosine-protein kinase activity.
Tissue specificityExpressed in primary and metastatic colon tumors and in normal colon tissue. Tumors may express a different isoform to that found in normal tissue.
Involvement in diseaseNote=A chromosomal aberration involving PDGFRA is found in some cases of hypereosinophilic syndrome. Interstitial chromosomal deletion del(4)(q12q12) causes the fusion of FIP1L1 and PDGFRA (FIP1L1-PDGFRA).
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 5 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
- Information by UniProt
- Alpha-type platelet-derived growth factor receptor antibody
- CD140 antigen-like family member A antibody
- CD140a antibody
All lanes : Anti-PDGFR alpha (phospho Y720) antibody [EP2478] (ab134068) at 1/1000 dilution
Lane 1 : NIH 3T3 cell lysate, untreated
Lane 2 : NIH 3T3 cell lysate, treated with Pervanadate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 122 kDa
Observed band size: 190 kDa why is the actual band size different from the predicted?
Flow cytometry analysis of NIH/3T3 cells treated with 1mM Pervanadate for 30mins cells labeling PDGFR alpha (phospho Y720) with unpurified ab134068 at 1/200 dilution (0.0445µg) (red). Cells were fixed with 4% paraformaldehyde . Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/2000 dilution. Isotype control - Rabbit monoclonal IgG (ab172730 /Black). Unlabeled control - Cell without incubation with primary antibody and secondary antibody (Blue).
Flow Cytometry analysis of permeabilized NIH/3T3 cells labelling PDGFR alpha (phospho Y720) with ab134068. Green - untreated, Red - pervanadate-treated, Blue - preincubated with phospho-PDGF Receptor alpha (phospho Y720) peptide, Orange - preincubated with non-phospho-PDGR Receptor alpha peptide.
ab134068 has been referenced in 3 publications.
- Sanada TJ et al. Characterization of pulmonary intimal sarcoma cells isolated from a surgical specimen: In vitro and in vivo study. PLoS One 14:e0214654 (2019). PubMed: 30925179
- Stivala S et al. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest 130:1596-1611 (2019). PubMed: 30730307
- Kiseleva AA et al. Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs. Clin Cancer Res 25:4179-4193 (2019). PubMed: 30867219